ALT (SGPT) < 10 x upper limit of normal (ULN) for age
ALT (SGPT) < 10 x upper limit of normal (ULN) for age
PIK3CA WILD TYPE COHORT (closed 03/17/2016): AST(SGOT)/ and ALT(SGPT) =< 2.5 X institutional upper limit normal
ENDOCRINE RESISTANT AND ADJUVANT COHORT: AST(SGOT)/ and ALT(SGPT) =< 2.5 X institutional upper limit normal
SGPT (ALT) =< 5 x upper limit of normal (ULN) for age
AST (SGOT) and ALT (SGPT) ? 2.5 × institutional upper limit of normal (ULN) [? 5 × ULN in presence of liver metastases]
AST (SGOT)/ALT (SGPT) ?5 X institutional upper limit of normal if with liver metastases; ?2.5 X ULN if no liver metastases
INCLUSION CRITERIA FOR STRATUM C: ALT (SGPT) =< 3 x institutional upper limit of normal
AST/SGOT and ALT/SGPT < 2.5 x the institutional upper limit of normal (IULN).
PART II: SGOT and SGPT =< 3 x upper limit of normal (ULN)
AST (SGOT)/ALT(SGPT) (only if elevated liver function tests [LFTs] are due to disease) =< 5.0 x institutional upper limit of normal
PHASE II: AST (SGOT) =< 2.5 x institutional upper limit of normal
PHASE II: ALT (SGPT) =< 2.5 x institutional upper limit of normal
PHASE II SCLC: AST (SGOT)/ALT (SGPT) =< 2.5 X institutional upper limit of normal (=< 5X ULN if liver mets)
UROTHELIAL CARCINOMA EXPANSION COHORT: AST(SGOT)/ALT(SGPT) =< 2.5 X institutional upper limit of normal (=< 5X ULN if liver mets)
mCRPC EXPANSION COHORT: AST(SGOT)/ALT(SGPT) =< 3 X institutional upper limit of normal (=< 5X ULN if liver mets)
Transaminases (AST/SGOT and ALT/SGPT) ? 2.5 times upper limit of normal
AST(SGOT)/ALT(SGPT) > 2.5 x institutional upper limit of normal
PHASE II STUDY COHORT 5 TRIPLE NEGATIVE BREAST CANCER ELIGIBILITY CRITERIA (MEDI+O ONLY):\r\nAST(SGOT)/ALT(SGPT) =< 2.5 X institutional upper limit of normal (ULN); for subjects with liver metastases, AST or ALT =< 5 × ULN
PHASE II STUDY METASTATIC CASTRATE-RESISTANT PROSTATE CANCER COHORT 4 ELIGIBILITY CRITERIA (MEDI+O ONLY):\r\nAST(SGOT)/ALT(SGPT) =< 2.5 X institutional upper limit of normal (ULN); for subjects with liver metastases, AST or ALT =< 5 × ULN
PHASE II COLORECTAL CANCER COHORT 6 (MEDI+C ONLY):\r\nAST(SGOT)/ALT(SGPT) =< 2.5 X institutional upper limit of normal (ULN); for subjects with liver metastases, AST or ALT =< 5 X ULN
Newly diagnosed MCL: AST (SGOT) and ALT (SGPT) < 2 x upper limit of normal or < 5 x upper limit of normal if hepatic metastases are present
Patients must have normal organ and marrow function as defined below: leukocytes > 3,000/mcL; absolute neutrophil count >1,500/mcL; platelets > 100,000/mcL, total bilirubin < or = 2.0 mg/dL. (Does NOT apply to patients with Gilbert's Syndrome); AST(SGOT)/ALT(SGPT) < 2.5 X institutional upper limit of normal (patients with liver involvement will be allowed < or = 5.0 X institutional upper normal limit) serum creatinine < 2.0 mg/dL
ELIGIBILITY CRITERIA FOR REGISTRATION: AST(SGOT)/ALT(SGPT) =< 2.0 x institutional upper limit of normal (within one week of registration if patient postop, otherwise within two weeks of registration)
AST/SGOT and ALT/SGPT ?2.5×ULN. (upper limit of normal)
SGOT (AST)<3x upper limit of normal
Adequate hepatic function as documented by serum bilirubin< 1.5 mg/dl and SGOT and SGPT 1.5 or less x upper limit of normal.
ALT (SGPT): < 2.5 X institutional upper limit of normal
AST (SGOT)/ALT (SGPT) less than or equal to 2.5 x institutional upper limit of normal (ULN) or less than or equal to 5.0 x ULN in patients with liver metastases
SGPT (ALT) and SGOT (AST) < 3 x upper limit of normal (for ALT, the upper limit of normal for all sites is defined as 45 U/L)
TREATMENT: AST (SGOT)/ALT (SGPT) =< 3 x institutional upper limit of normal
DOSE EXPANSION COHORT: AST(SGOT) ? 2.5 X institutional upper limit of normal (ULN)
Secondary Registration: AST (SGOT)/ALT (SGPT) =< 2.0 x institutional upper limit of normal
PHASE II: AST (SGOT)/ALT (SGPT) =< 3 X institutional upper limit of normal (ULN) or =< 5 X ULN if the patient has liver metastases
AST (SGOT), ALT (SGPT) ? 2.5 x upper limit of normal (ULN),
ALT (SGPT) and/or AST (SGOT) ? 3x upper limit of normal (ULN), or ? 4 x ULN (if upon judgment of the treating physician, it is believed to be due to extramedullary hematopoiesis [EMH] related to MF);
Adequate biochemistry laboratory results (AST/SGOT and ALT/SGPT ? 3.0 x upper limit of normal; bilirubin ? 2.0 mg/dL; creatinine clearance of ? 40 mL/min).
PHASE II: AST (SGOT)/ALT (SGPT) =< 2.5 x institutional upper limit of normal
AST/SGOT and ALT/SGPT =< 2.5 x upper limit of normal (ULN) if liver metastases are present
SGOT(AST) and SGPT(ALT) < 3 x ULN (upper limit of normal)
AST(SGOT)/ALT(SGPT) <2.5 X institutional upper limit of normal
AST(SGOT)/ALT(SGPT) ? 2.5 X institutional upper limit of normal
AST(SGOT)/ALT(SGPT) ? 2.5 X institutional upper limit of normal
EXPANSION COHORT ONLY: AST (SGOT)/ALT (SGPT) =< 2.5 X institutional upper limit of normal
AST(SGOT)/ALT(SGPT) <1.5 X institutional upper limit of normal
SGPT < 2X upper limit of normal.
Patient's ALT must be < 5 x institutional upper limit of norm ULN.
ALT (SGPT) ? 2.5 x upper limits of normal
AST, SGOT, ALT, SGPT ? 2.5 X upper limit of normal, < 5 upper limit if there are liver metastases
Serum SGOT/AST or SGPT/ALT > 3.0 x upper limit of normal (ULN)
SGOT (AST) < 3x upper limit of normal.
AST/(SGOT)/ALT(SGPT) =< 3.0 x institutional upper limit of normal (ULN) (=< 5.0 x institutional ULN with documented liver metastases)
SGOT (AST) or SGPT (ALT) < 5.0 x upper limit of normal
AST/SGOT and ALT/SGPT ?2 x Upper Limit of Normal (ULN)
AST (SGOT)/ALT (SGPT) < 2.5 X institutional upper limit of normal
AST (SGOT)/ALT (SGPT) < 2.5 X institutional upper limit of normal
AST (SGOT)/ALT (SGPT) < 2.5 X institutional upper limit of normal
